NDA 212320 · Shield Tx
Accrufer
Ferric Maltol · Oral
NovelLast checked: Nov 20, 2026Latest source record: Dec 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jul 25, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
8 Phase 3, 1 recruiting
FAERS reports
1,060
214 serious, 42 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 2, 2026.
ACCRUFER is indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older. ACCRUFER is an iron replacement product indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older. ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2025 Supplement 19 · Efficacy · priority review LabelLetter
- Jul 25, 2019 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- ACCRUFER · FERRIC MALTOL 30MG IRON · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ferric Maltol" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBDPivotal-lookingCompleted
Shield TherapeuticsIndustry
NCT02680756 · 250 participants · Start Jan 2016 · Primary completion Oct 2018
Drug: Ferric Maltol; Ferric Carboxy Maltose · For: Anemia, Iron-Deficiency; Inflammatory Bowel Disease; Crohn's Disease
Sites: Dothan, Alabama; Tucson, Arizona; Gainesville, Florida · 44 sites in all
- Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney DiseasePivotal-lookingCompleted
Shield TherapeuticsIndustry
NCT02968368 · 167 participants · Start Dec 1, 2016 · Primary completion Jan 18, 2018
Drug: Ferric maltol · For: Renal Insufficiency, Chronic; Iron-Deficiency Anemia
Sites: Peoria, Arizona; Phoenix, Arizona; Prescott, Arizona · 27 sites in all
- Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient WomenPivotal-lookingRecruiting
Pharmanutra S.p.a.Industry
NCT07308769 · 146 participants (planned) · Start Dec 11, 2025 · Primary completion Oct 2026
Drug: Ferric Maltol (Feraccru®) · For: Anemia; Iron Deficiency Anemia (IDA)
Sites: Barcelona, Spain; Málaga, Spain; Sant Cugat del Vallès, Spain · 7 sites in all
- Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)Pivotal-lookingCompleted
Shield TherapeuticsIndustry
NCT01352221 · 128 participants · Start Aug 2011 · Primary completion Oct 2013
Drug: ST10; Placebo oral capsule · For: Iron Deficiency Anaemia; Inflammatory Bowel Disease; Crohn's Disease
- Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)Pivotal-lookingCompleted
Shield TherapeuticsIndustry
NCT01340872 · 128 participants · Start Aug 2011 · Primary completion Oct 2013
Drug: ST10-021; Placebo Comparator · For: Iron Deficiency Anaemia; Inflammatory Bowel Disease; Ulcerative Colitis
- Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel DiseasePivotal-lookingCompleted
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
NCT07739368 · 122 participants · Start Sep 1, 2021 · Primary completion Feb 20, 2025
Drug: Ferric Maltol; Placebo Oral Capsule · For: Iron Deficiency Anaemia
Sites: Nanjing, China
- Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel DiseaseStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT05456932 · 90 participants (planned) · Start Aug 19, 2022 · Primary completion Aug 31, 2023
Drug: Intravenous iron; Ferric maltol and 1 more · For: Inflammatory Bowel Diseases; Iron-deficiency; Iron Deficiency Anemia
Sites: Amsterdam, Netherlands; Groningen, Netherlands; Leiden, Netherlands · 5 sites in all
Shield TherapeuticsIndustry
NCT05126901 · 65 participants · Start Nov 3, 2021 · Primary completion Jun 9, 2024
Drug: Ferric Maltol; Ferrous sulfate · For: Anemia; Iron-deficiency
Sites: Saraland, Alabama; Homestead, Florida; Kissimmee, Florida · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- constipation160
- inappropriate schedule of product administration108
- abdominal discomfort104
- diarrhoea103
- nausea99
- abdominal pain upper75
- maternal exposure during pregnancy71
- treatment noncompliance61
- drug ineffective51
- off label use42
- death39
- vomiting34
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 35 |
| 2023 | 93 |
| 2024 | 272 |
| 2025 | 576 |
| 2026 | 69 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
Howaldt S, Domènech E, Martinez N, et al. · Inflamm Bowel Dis 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension.
Pergola PE, Kopyt NP · Am J Kidney Dis 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Interventions for fatigue in inflammatory bowel disease.
Farrell D, Artom M, Czuber-Dochan W, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.
Schmidt C, Ahmad T, Tulassay Z, et al. · Aliment Pharmacol Ther 2016 · Clinical Trial, Phase III, Multicenter Study
- Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.
Bokemeyer B, Krummenerl A, Maaser C, et al. · Eur J Drug Metab Pharmacokinet 2017 · Clinical Trial, Phase I, Randomized Controlled Trial
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Systematic Review
Sponsor: Shield Tx
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.